Browse studies

Find your next paid study

1,260 recruiting studies matching your filters

Phase I Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors in Participants With Metastatic Solid Tumors With KRAS G12V Mutations

This phase I trial studies the side effects and best dose of autologous CD8+ and CD4+ transgenic T cells expressing high affinity KRASG12V mutation-specific T …

Non-small Cell Lung CancerPancreas CancerColon Cancer

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Fred Hutchinson Cancer CenterNCT06043713

Phase 1

An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations

Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worl…

Non Small Cell Lung Carcinomac-MET

Estimated

~$150 – $4,500

Actual pay is set by the research site.

AbbVieNCT06772623

Phase 2

Cashew Allergy Study in Children: Assessing Desensitization, Efficacy, and Safety (CASCADES Study)

The CASCADES study will investigate the safety and efficacy of sublingual immunotherapy (SLIT) for the treatment of cashew allergy in children ages 1-11 years …

Cashew Nut AllergyTree Nut Allergies

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of North Carolina, Chapel HillNCT07170540

Phase 1

A Phase 1a/1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and…

Locally Advanced Solid TumorMetastatic Solid Tumor

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Nuvalent Inc.NCT06521554

Phase 1

A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

This phase I trial tests the safety, side effects and best dose of futibatinib with paclitaxel and ramucirumab for the treatment of patients with gastric, gast…

Clinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8+13 more

Estimated

Phase 2

A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy …

Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer+1 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

AbbVieNCT06890338

Phase 1

A Phase 1b/2 Open-label Study Evaluating Different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-Based Regimens in First-line Extensive Stage Small Cell Lung Cancer

Researchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the…

Small Cell Lung Cancer Extensive Stage

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Merck Sharp & Dohme LLCNCT07227597

Phase 3

A Randomized, Open-label, Phase 3 Study of Setidegrasib (ASP3082) Versus Docetaxel in Participants With KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on or After Platinum Based Chemotherapy and Checkpoint Inhibitor Therapy (CPI)

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. The first treatment is usually chemotherapy, given with another treatment that targe…

Non-small Cell Lung Cancer (NSCLC)

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Astellas Pharma Global Development, Inc.NCT07566052

Phase 1

First in Human Phase 1 Study of AOH1996 in Patients With Refractory Solid Tumors

This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory). AOH1…

Refractory Malignant Solid NeoplasmOsteosarcomaLeiomyosarcomas+4 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

City of Hope Medical CenterNCT05227326

Phase 1

Open Label, Multicenter, Dose-escalation and Cohort-expansion Phase I/IIA Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer (CRC) - BreAK CRC Trial (BreAK for Brenus Anti-cancer)

This is a phase I/IIA, first-in-human (FIH), two-part, open-label, multicenter study to characterize the safety, tolerability profile, and clinical efficacy of…

Unresectable Metastatic Colorectal CancerUnresectable Locally Advanced Colorectal Cancer

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Brenus PharmaNCT06934538

Phase 3

DAREON ® -Lung-1: A Phase III Multi-center, Open-label, Randomised Trial of Intravenous Obrixtamig in Combination With Atezolizumab, Carboplatin, and Etoposide vs. Atezolizumab, Carboplatin, and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer

This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus s…

Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Estimated

~$50 – $2,250

Actual pay is set by the research site.

Boehringer IngelheimNCT07472517

Phase 3

A Randomized, Multiregional, Open-Label Phase 3 Clinical Trial of ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%-85% of lung cancers cases. Squamous carcinoma accounts for 20-30%…

Non-Small Cell Lung Cancer

Estimated

~$50 – $2,250

Actual pay is set by the research site.

AbbVieNCT07756645